Arrhythmogenic effects and cardioprotective effects of dapagliflozin against radiotherapy induced cardiac damage

Abstract Background With increasing incidence of cancer among the adult population, radiotherapy (RT) is frequently used as a critical component in the treatment of various cancer types. Due to the nature of ionizing radiation, damage usually occurs within the tissues in anatomical neighborhood with the primary tumor localisation. Dapagliflozin (DAPA), originally developed as an oral anti-diabetic medication, has shown to have potent cardioprotective effects in the DAPA-HF trial. In this study, we aimed to investigate cardioprotective effects of Dapagliflozin against radiotherapy induced cardiac cellular damage. Methods A total of 40 male rats were obtained, and were subjected to a 10 day pretreatment period to accommodate laboratory settings. Afterwards, rats were divided into 4 groups consisting of 10 each (control = 10, dapagliflozin = 10, radiotherapy = 10, radiotherapy + dapagliflozin = 10). Meanwhile, radiotherapy and radiotherapy + dapagliflozin groups received a single dose of 20 Gray (Gy) X-ray to 4 x 4 cm area at 0.60 Gy/min, and dapagliflozin and radiotherapy + dapagliflozin groups were gavaged daily with 10 mg/kg dapagliflozin. In the second week of the study, rats were examined by echocardiography and electrocardiogram. Furthermore, histopathological method was used to evaluate the level of cardiotoxicity. Results Ejection fraction value decreased was 17.3% lower in the DAPA + RT group, compared with the RT group (p < 0.001). In addition, QTc prolongation and QRS widening were 11.5% and 17.4% more in the RT group, compared with the DAPA + RT group, respectively (p < 0.001 for both values). While the sarcomyolysis, inflammatory cell infiltration, and necrotic changes were found to be severe in the RT group, the DAPA + RT group had 68% lower sarcomyolysis, 64% lower inflammatory cell infiltration, and 55% lower necrosis (p < 0.001 for all values). Conclusions In our study, we observed the protective effects of DAPA against LV remodeling and dysfunction in RT-induced cardiomyopathy model. Cardiomyopathy, Left Ventricular Dysfunction, Radiotherapy, SGLT2 inhibitorsStudy Design

Authors

Institutions

Publication Details

Journal
EP Europace
Published
2025-05-01
DOI
https://doi.org/10.1093/europace/euaf085.519
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Arrhythmogenic effects and cardioprotective effects of dapagliflozin against radiotherapy induced cardiac damage

Emine Elif Özkan, Şerife Ulusan, Kanat Gülle, S. Aydoğdu et al.
EP Europace
Chemotherapy-induced cardiotoxicity and mitigation
article

Arrhythmogenic effects and cardioprotective effects of dapagliflozin against radiotherapy induced cardiac damage

Emine Elif Özkan, Şerife Ulusan, Kanat Gülle, S. Aydoğdu, Alper Özseven, Hüseyin Emre Cebeci, Adnan Karaibrahimoğlu, Abdülsamet Erden, Mevlüt Serdar Kuyumcu, Atalay Şahin, Kadir Şeker, Mehmet Hakan Uzun, Selim Süleyman Sert, Muhammet Ali Ekiz
article en

Abstract

Abstract Background With increasing incidence of cancer among the adult population, radiotherapy (RT) is frequently used as a critical component in the treatment of various cancer types. Due to the nature of ionizing radiation, damage usually occurs within the tissues in anatomical neighborhood with the primary tumor localisation. Dapagliflozin (DAPA), originally developed as an oral anti-diabetic medication, has shown to have potent cardioprotective effects in the DAPA-HF trial. In this study, we aimed to investigate cardioprotective effects of Dapagliflozin against radiotherapy induced cardiac cellular damage. Methods A total of 40 male rats were obtained, and were subjected to a 10 day pretreatment period to accommodate laboratory settings. Afterwards, rats were divided into 4 groups consisting of 10 each (control = 10, dapagliflozin = 10, radiotherapy = 10, radiotherapy + dapagliflozin = 10). Meanwhile, radiotherapy and radiotherapy + dapagliflozin groups received a single dose of 20 Gray (Gy) X-ray to 4 x 4 cm area at 0.60 Gy/min, and dapagliflozin and radiotherapy + dapagliflozin groups were gavaged daily with 10 mg/kg dapagliflozin. In the second week of the study, rats were examined by echocardiography and electrocardiogram. Furthermore, histopathological method was used to evaluate the level of cardiotoxicity. Results Ejection fraction value decreased was 17.3% lower in the DAPA + RT group, compared with the RT group (p < 0.001). In addition, QTc prolongation and QRS widening were 11.5% and 17.4% more in the RT group, compared with the DAPA + RT group, respectively (p < 0.001 for both values). While the sarcomyolysis, inflammatory cell infiltration, and necrotic changes were found to be severe in the RT group, the DAPA + RT group had 68% lower sarcomyolysis, 64% lower inflammatory cell infiltration, and 55% lower necrosis (p < 0.001 for all values). Conclusions In our study, we observed the protective effects of DAPA against LV remodeling and dysfunction in RT-induced cardiomyopathy model. Cardiomyopathy, Left Ventricular Dysfunction, Radiotherapy, SGLT2 inhibitorsStudy Design

EP EuropaceVol. 27(Supplement_1)
Suleyman Demirel University (KZ)
Openalex Percentile: Top 79%
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.